OTCMKTS:IMUC

EOM Pharmaceuticals (IMUC) Stock Forecast, Price & News

$0.28

0.00 (0.00%)

(As of 09/21/2023 ET)

Compare

Today's Range: $0.28
▼
$0.28
50-Day Range: $0.16
▼
$0.40
52-Week Range: $0.15
▼
$0.94

Volume: 10,027 shs
Average Volume: 4,243 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Financials Headlines SEC Filings Short Interest

About EOM Pharmaceuticals (OTCMKTS:IMUC) Stock

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

IMUC Price History

30 days | 90 days | 365 days | Advanced Chart

IMUC Stock News Headlines

September 14, 2023 | americanbankingnews.com

EOM Pharmaceuticals (OTCMKTS:IMUC) Trading Down 25.2%

September 6, 2023 | finance.yahoo.com

EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil

September 22, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

August 17, 2023 | uk.finance.yahoo.com

Q2 2023 PAVmed Inc Earnings Call

August 3, 2023 | msn.com

EOM Pharmaceuticals shelves plans to uplist shares, raise $15M

July 17, 2023 | benzinga.com

Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock

July 3, 2023 | marketwatch.com

Amneal Pharmaceuticals: FDA Requests Additional Information on IPX203 Ingredient

June 14, 2023 | marketwatch.com

Amneal Pharmaceuticals Gets FDA Approval for Injectable Tumor Treatment

September 22, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

May 16, 2023 | msn.com

Trade commission fights Amgen's $28B purchase of Horizon Therapeutics

May 10, 2023 | msn.com

Pharma CEOs to testify in U.S. Senate hearing on insulin prices

May 10, 2023 | marketwatch.com

8-K: Acumen Pharmaceuticals, Inc.

May 9, 2023 | msn.com

Olema Pharmaceuticals GAAP EPS of -$0.70 misses by $0.04

May 9, 2023 | investing.com

OliX Pharmaceuticals Inc (226950)

March 30, 2023 | msn.com

USFDA gives final nod to Alembic Pharmaceuticals’ Glaucoma drug

March 27, 2023 | reuters.com

U.S. Supreme Court mulls Amgen bid to revive cholesterol drug patents

March 13, 2023 | marketwatch.com

Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains

March 11, 2023 | finance.yahoo.com

EOM Pharmaceuticals Holdings, Inc. (IMUC)

February 24, 2023 | seekingalpha.com

Ionis Pharmaceuticals, Inc. (IONS) Q4 2022 Earnings Call Transcript

December 8, 2022 | technews.tmcnet.com

AltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological Diseases

November 29, 2022 | marketwatch.com

Alaunos Therapeutics Shares Drop 24% After Public Offering Prices

October 6, 2022 | marketwatch.com

InVivo Therapeutics Adds to Surge After Hours, Recently at $10.85

October 3, 2022 | benzinga.com

Imunon Appoints James E. Dentzer to its Board of Directors

September 21, 2022 | morningstar.com

Seres Therapeutics Inc MCRB Stock Quote

September 14, 2022 | benzinga.com

ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference

September 11, 2022 | reuters.com

ImmunoCellular Therapeutics Ltd

June 28, 2022 | seekingalpha.com

EOM Pharmaceutical Files For $25 Million IPO Uplisting To Nasdaq

See More Headlines

Receive IMUC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EOM Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IMUC Company Calendar

Last Earnings: 8/13/2018
Today: 9/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:IMUC
CUSIP: N/A
CIK: 822411
Web: www.imuc.com
Phone: (201) 351-0605
Fax: 818-224-5287
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 1.26

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Irach B. Taraporewala B.S. (Age 67)
M.S., Ph.D., CEO, Pres & Director
Comp: $265.65k

Mr. Wayne I. Danson CPA (Age 69)
CFO & Treasurer
Comp: $150k

Mr. Eli Goldberger (Age 33)
Founder, Chairman & COO

Dr. Shalom Z. Hirschman M.D. (Age 87)
Co-Founder, Chief Scientific Officer & Medical Director

Key Competitors

View All Competitors

IMUC Stock - Frequently Asked Questions

How have IMUC shares performed in 2023?: EOM Pharmaceuticals' stock was trading at $0.8197 at the beginning of 2023. Since then, IMUC shares have decreased by 65.8% and is now trading at $0.28.
View the best growth stocks for 2023 here.
How were EOM Pharmaceuticals' earnings last quarter?: EOM Pharmaceuticals Holdings, Inc. (OTCMKTS:IMUC) announced its earnings results on Monday, August, 13th. The company reported ($0.01) earnings per share for the quarter.

What is EOM Pharmaceuticals' stock symbol?: EOM Pharmaceuticals trades on the OTCMKTS under the ticker symbol "IMUC."
How do I buy shares of EOM Pharmaceuticals?: Shares of IMUC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is EOM Pharmaceuticals' stock price today?: One share of IMUC stock can currently be purchased for approximately $0.28.
How can I contact EOM Pharmaceuticals?: EOM Pharmaceuticals' mailing address is 23622 CALABASAS ROAD SUITE 300, CALABASAS CA, 91302. The official website for the company is www.imuc.com. The company can be reached via phone at (201) 351-0605, via email at ir-pr@imuc.com, or via fax at 818-224-5287.

This page (OTCMKTS:IMUC) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial